Company stock · NYSE EURONEXT - EURONEXT BRUSSELS · USD

ARGX

argenx SE

—

Price unavailable — company details still show below

Industry: Biotechnology
Market value: $49.3 billion
Number of shares: 62.9 million
Country: NL
Went public: Jul 10, 2014
Exchange: NYSE EURONEXT - EURONEXT BRUSSELS
Website: argenx.com

Compare →Earnings calendar →

Price chart Pro

Loading chart…

Company briefing

What ARGX is

Plain English context — why the name shows up in the news, and what to watch next.

In plain English

argenx SE is a Dutch biotechnology company that develops biologic medicines, most notably the antibody drug Vyvgart used to treat…

Recent headlines

Live company news for ARGX — each headline includes a ClearTape brief in plain English; open the original for the full story.

argenx (ENXTBR:ARGX) Reports Positive Phase 3 Data In Autoimmune MyositisIn brief
Argenx announced that its Phase 3 ALKIVIA trial for VYVGART in autoimmune myositis met the primary endpoint, showing clinically meaningful improvement over placebo in both IMNM and dermatomyositis groups. The company plans to present the data at a major scientific conference in 2026.
Yahoo · Oct 24, 2026
Argenx (ENXTBR:ARGX) Stock Faces Margin Questions After Q3 EarningsIn brief
Argenx’s Q3 2026 earnings showed product sales of about US$1.7 billion and basic earnings per share of US$8.07, with a trailing net margin of 31.7%. The stock price remained flat, indicating investors are still evaluating how much of this performance is priced in.
Yahoo · Oct 24, 2026
Argenx's Vyvgart Sales Growth, Pipeline Progress Support Outlook, Oppenheimer SaysIn brief
Argenx’s Q3 results highlighted continued growth in Vyvgart sales, while its acquisition of F…
Yahoo · Oct 23, 2026
Argenx's Vyvgart Beats Expectations With Focus Shifting to December Data, RBC SaysIn brief
Headline: Argenx's Vyvgart Beats Expectations With Focus Shifting to December Data, RBC Says.
Yahoo · Oct 23, 2026
Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $1190In brief
Morgan Stanley analyst Sean Laaman maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1140 to $1190. The headline: Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $1190.
Benzinga · Oct 23, 2026
argenx: 3 Key Takeaways for Long-Term InvestorsIn brief
Pipeline expansion into new indications could sustain growth long after VYVGART matures, a rare diversification for a single-drug biotech. The headline: argenx: 3 Key Takeaways for Long-Term Investors.
Yahoo · Oct 23, 2026
Guggenheim Maintains Buy on argenx, Lowers Price Target to $1120In brief
Guggenheim analyst Yatin Suneja maintains argenx (NASDAQ:ARGX) with a Buy and lowers the price target from $1185 to $1120. The headline: Guggenheim Maintains Buy on argenx, Lowers Price Target to $1120.
Benzinga · Oct 23, 2026
Wells Fargo Maintains Overweight on argenx, Lowers Price Target to $1336In brief
Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and lowers the price target from $1356 to $1336. The headline: Wells Fargo Maintains Overweight on argenx, Lowers Price Target to $1336.
Benzinga · Oct 23, 2026

Latest on this name

Insights & deeper context

1 recent card — open any for the full deeper dive.

CompanyShort-termUpbeatDays to weeksBenzingaARGX

Snowflake To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday

In brief

Citizens Securities lifted Snowflake Inc.

Open card →

Company reports

Official filings (US SEC and linked cards)

No filings here yet

Official report cards for ARGX will show up here when available.

Broad market indexes (like the S&P 500, a basket of 500 large US companies) are shown through popular funds that track them (for example SPY). Company profile and prices use live market data when available.